Latus Bio closed a $97 million Series A financing to support a pipeline based on AAV capsid variants. The company expects the cash to fund operations through clinical milestones including initial clinical data for its Huntington’s disease program (LTS-201) and CLN2 disease program (LTS-101). The funding underscores renewed investor appetite for next-generation gene therapy delivery engineering, particularly capsid optimization strategies designed to improve performance and broaden dosing feasibility. Latus is framing its approach around potentially enabling efficient delivery at scale, not only for ultra-rare indications. For the category, this is another marker that the market continues to fund AAV platform companies that can demonstrate differentiable delivery properties early in development.